Related Experiment Video
Updated: Apr 1, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.6K
New levodopa therapeutic strategies.
1Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, 6777 West Maple Road, West Bloomfield, MI 48322, USA.
Parkinsonism & Related Disorders
|October 14, 2015
Summary
Levodopa therapy offers Parkinson's disease symptom relief but faces challenges with consistent drug delivery. New formulations aim to improve treatment by providing steadier levodopa levels, reducing motor fluctuations for patients.
Area of Science:
- Neurology
- Pharmacology
- Drug Delivery Systems
Background:
- Levodopa has been a cornerstone therapy for Parkinson's disease for nearly 50 years, significantly alleviating motor symptoms.
- Its full therapeutic potential is still being explored, extending beyond its role as a dopamine precursor.
- Current immediate-release formulations exhibit variable pharmacokinetic profiles, leading to motor fluctuations in patients.
Purpose of the Study:
- To review the current state and future directions of levodopa formulations for Parkinson's disease.
- To highlight the need for improved drug delivery to enhance therapeutic constancy.
- To discuss novel delivery systems addressing pharmacokinetic variability.
Main Methods:
- Review of existing literature and recently approved/under-development levodopa formulations.
- Analysis of pharmacokinetic challenges associated with conventional levodopa delivery.
- Identification of emerging drug delivery technologies for levodopa.
Main Results:
- Conventional carbidopa-levodopa tablets show significant pharmacokinetic variability.
- Several advanced formulations are emerging to improve levodopa delivery constancy.
- These include intestinal infusion, sustained-release microtablets, gastric-retentive systems, prodrugs, inhalation, and subcutaneous infusion.
Conclusions:
- Improving the constancy of levodopa delivery is critical for optimizing Parkinson's disease treatment.
- Novel formulations represent the next frontier in managing motor fluctuations.
- These advancements promise more stable therapeutic effects and improved patient outcomes.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
2.0K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.0K
01:28Drug Therapy
408
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
408
01:29Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
01:26Cholinergic Antagonists: Therapeutic Uses
1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K